US4738843A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-tumor substance of immunoglobulin and melphalan and process for producing the same
Assignee: Kureha Corp
•
Filing: 1987-01-20
•
Granted: 1988-04-19
•
Expires: 2007-01-20
Abstract
Abstract Disclosed herein are an anti-tumor substance obtained by bonding an anti-tumor agent to human immunoglobulin, and a process for producing the same.
Inventors
- 👤 Yoshiharu Oguchi
- 👤 Koichi Niimura
- 👤 Takayoshi Fujii
- 👤 Masahiko Fujii
- 👤 Kenichi Matsunaga
- 👤 Chikao Yoshikumi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 12:32
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/395; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6807; A61K47/6809; A61P; A61P35/00; Y; Y10; Y10S; Y10S424/00; Y10S424/809; Y10S530/00; Y10S530/866
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
108 words
An anti-tumor substance manufactured by a process comprising: (a) dissolving melphalan or ester thereof in aqueous solvent; (b) adding a bonding agent, selected from the group consisting of carbodiimides, glutaraldehyde, diethylmalonimidate, isocyanate and polyglutamic acid, to the aqueous solution, and then adding human immunoglobulin obtained from a normal healthy person to said aqueous solution, and thereby reacting said human immunoglobulin and said melphalan or ester thereof at a temperature of -30° to 50° C. for 1 minute to 48 hours; and (c) subjecting the thus produced reaction product to purification by means of a method selected from the group consisting of salting out, precipitation, recrystallization, elution and column-fractionation.
Claim 2
Dependent Claim
108 words
An anti-tumor substance manufactured by a process comprising: (a) dissolving melphalan or ester thereof in aqueous solvent; (b) adding a bonding agent, selected from the group consisting of carbodiimides, glutaraldehyde, diethylmalonimidate, isocyanate and polyglutamic acid, to the aqueous solution, and then adding human immunoglobulin obtained from a normal healthy person to said aqueous solution, and thereby reacting said human immunoglobulin and said melphalan or ester thereof at a temperature of -30° to 50° C. for 1 minute to 48 hours; and (c) subjecting the thus produced reaction product to purification by means of a method selected from the group consisting of salting out, precipitation, recrystallization, elution and column-fractionation.
Claim 3
Dependent Claim
14 words
The anti-tumor substance according to claim 1, wherein said bonding agent is a carbodiimide.
Claim 4
Dependent Claim
25 words
The anti-tumor substance according to claim 2, wherein said carbodiimide is one selected from the group consisting of 1-ethyl-3,3-dimethylaminopropyl carbodiimide, dicyclohexyl carbodiimide and morpholinoethyl carbodiimide.
Claim 5
Dependent Claim
15 words
The anti-tumor substance according to claim 1, wherein said ester is a lower alkyl ester.
Claim 6
Dependent Claim
16 words
The anti-tumor substance according to claim 4, wherein said lower alkyl ester is a methyl ester.
Claim 7
Dependent Claim
13 words
The anti-tumor substance according to claim 1, wherein said human immunoglobulin is IgG.
Claim 8
Dependent Claim
15 words
The anti-tumor substance according to claim 1, wherein said human immunoglobulin is F(ab') 2 .
Claim 9
Dependent Claim
53 words
A pharmaceutical composition in dosage unit form comprising an effective amount of an anti-tumor substance obtained by bonding melphalan or ester thereof to human immunoglobulin derived from a normal healthy person using a bonding agent, selected from the group consisting of carbodiimides, glutaraldehyde, diethylmalonimidate, isocyanate and polyglutamic acid, as the active ingredient thereof.
Claim 10
Dependent Claim
53 words
A pharmaceutical composition in dosage unit form comprising an effective amount of an anti-tumor substance obtained by bonding melphalan or ester thereof to human immunoglobulin derived from a normal healthy person using a bonding agent, selected from the group consisting of carbodiimides, glutaraldehyde, diethylmalonimidate, isocyanate and polyglutamic acid, as the active ingredient thereof.
Claim 11
Dependent Claim
13 words
The pharmaceutical composition according to claim 8, wherein said bonding agent is carbodiimide.
Claim 12
Dependent Claim
25 words
The pharmaceutical composition according to claim 9, wherein said carbodiimide is one selected from the group consisting of 1-ethyl-3,3-dimethylaminopropyl carbodiimide, dicyclohexyl carbodiimide and morpholinoethyl carbodiimide.
Claim 13
Dependent Claim
15 words
The pharmaceutical composition according to claim 8, wherein said ester is a lower alkyl ester.
Claim 14
Dependent Claim
16 words
The pharmaceutical composition according to claim 11, wherein said lower alkyl ester is a methyl ester.
Claim 15
Dependent Claim
13 words
The pharmaceutical composition according to claim 8, wherein said human immunoglobulin is IgG.
Claim 16
Dependent Claim
15 words
The pharmaceutical composition according to claim 8, wherein said human immunoglobulin is F(ab') 2 .
Claim 17
Independent Claim
68 words
A method for treating a tumor selected from the group consisting of human cancers of breast, lung, esophagus, stomach, colon, kidney, prostate, gallbladder and bone marrow, which comprises administering an effective amount of a compound obtained by bonding melphalan or ester thereof to human immunoglobulin derived from a normal healthy person using a bonding agent selected from the group consisting of carbodiimides, glutaraldehyde, diethylmalonimidate, isocyanate and polyglutamic acid.
Claim 18
Independent Claim
68 words
A method for treating a tumor selected from the group consisting of human cancers of breast, lung, esophagus, stomach, colon, kidney, prostate, gallbladder and bone marrow, which comprises administering an effective amount of a compound obtained by bonding melphalan or ester thereof to human immunoglobulin derived from a normal healthy person using a bonding agent selected from the group consisting of carbodiimides, glutaraldehyde, diethylmalonimidate, isocyanate and polyglutamic acid.
Claim 19
Dependent Claim
13 words
The method according to claim 15, wherein said bonding agent is a carbodiimide.
Claim 20
Dependent Claim
24 words
The method according to claim 16, wherein said carbodiimide is one selected from the group consisting of 1-ethyl-3,3-dimethylaminopropyl carbodiimide, dicyclohexyl carbodiimide and morpholinoethyl carbodiimide.
Claim 21
Dependent Claim
14 words
The method according to claim 15, wherein said ester is a lower alkyl ester.
Claim 22
Dependent Claim
15 words
The method according to claim 18, wherein said lower alkyl ester is a methyl ester.
Claim 23
Dependent Claim
13 words
The method according to claim 15, wherein said human immunoglobulin is Ig G.
Claim 24
Dependent Claim
14 words
The method according to claim 15, wherein said human immunoglobulin is F(ab') 2 .
References Cited (Backward Citations)
US4046722A
Cited
US4093607A
Cited
US4263279A
Cited
US4017471A
Cited
US4340535A
Cited
US4493793A
Cited
US4401592A
Cited
US4315851A
Cited
US4350626A
Cited
US4359457A
Cited
US4414148A
Cited
US4489710A
Cited
US4487714A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-04-19 | 1991-10-19 | 1992-04-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-04-19 | 1995-10-19 | 1996-04-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-04-19 | 1999-10-19 | 2000-04-19 | $7700.00 | Window Closed / Lapsed |